Publications by authors named "Zhongkun Xia"
Pancreatic ductal adenocarcinoma (PDAC) resists to current treatments due to its inherent tumor heterogeneity, therapy-resistant cancer stem/initiating cells survival, and immune evasion in the immunosuppressive tumor microenvironment (TME). Here, the results show that clinical PDAC and adjacent tissues undergo distinct chromatin remodeling. Multiple omics analysis revealed DEAD-box RNA helicase 18 (DDX18), a carcinogenic gene with similar H3K4me3 profile, is up-regulated and correlates with poor survival in PDAC patients.
View Article and Find Full Text PDFBackground And Purpose: Glioblastoma (GBM) is the most aggressive brain tumour in the central nervous system, but the current treatment is very limited and unsatisfactory. PGE -initiated cAMP signalling via EP and EP receptors is involved in the tumourigenesis of multiple cancer types. However, whether or how EP and EP receptors contribute to GBM growth largely remains elusive.
View Article and Find Full Text PDFHuman esophagus carcinoma (EC) is one of the most common malignant tumors, especially in Africa and Asia including China. In EC initiation and progression, genetic and epigenetic aberrations have been reported to play a major role, but the underlying molecular mechanisms are largely unknown. In this study, the miR-30e levels were analyzed in human EC tissues and TCGA databases, and the results demonstrated that miR-30e expression in EC tissues was significantly decreased compared to adjacent normal tissues.
View Article and Find Full Text PDFArticle Synopsis
- Hepatocellular carcinoma (HCC) is a deadly cancer with few effective treatments, but targeting the CDK4/6 and PI3K/AKT pathways shows promise.
- Researchers identified aminoquinol, an anti-plasmodium drug, as a new multi-kinase inhibitor that significantly reduces cell viability and induces apoptosis in cancer cells.
- In studies, aminoquinol demonstrated strong anti-tumor effects in mice and could be used alone or in combination with other treatments, showing potential as a new therapeutic strategy for HCC.
Article Synopsis
- Cyclin-dependent kinases 2/4/6 (CDK2/4/6) are important for cell cycle progression, and their deregulation is linked to hepatocellular carcinoma (HCC).
- Researchers combined computational and experimental methods to find a triple-inhibitor for CDK2/4/6 from FDA-approved drugs to treat HCC.
- They discovered vanoxerine dihydrochloride as an effective inhibitor, showing significant cytotoxic effects in HCC cell lines and promising anti-tumor activity in mice, suggesting it could be a new treatment option for HCC.
Esophagus cancer is the seventh cause of cancer-related deaths globally. In this study, we analyzed interleukin 6 (IL-6) gene expression in human esophagus cancer patients and showed that IL-6 mRNA levels are significantly higher in tumor tissues and negatively correlated with overall survival, suggesting that IL-6 is a potential therapeutic target for esophagus cancer. We further demonstrated that apigenin, a nature flavone product of green plants, inhibited IL-6 transcription and gene expression in human esophagus cancer Eca-109 and Kyse-30 cells.
View Article and Find Full Text PDF